Fampridine, the first drug designed to help people with multiple sclerosis walk, is now available on the NHS in England. This decision, previously rejected for cost, will benefit up to 5,000 people annually by boosting nerve signals for improved mobility.
Fampridine, the first drug designed to help people with multiple sclerosis walk, is now available on the NHS in England. This 'signal booster' drug, previously rejected for cost, could benefit up to 5,000 patients annually by improving mobility and independence, a decision welcomed by patients and the MS Society.
Fampridine, the first drug to aid walking for people with multiple sclerosis, is now available on the NHS in England. Up to 5,000 patients annually could benefit from the "signal booster" medication, which was previously rejected but is already available in other UK nations.
